

Thomas J Carmody

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9926294/publications.pdf>

Version: 2024-02-01

54
papers

5,201
citations

304743

22
h-index

168389

53
g-index

55
all docs

55
docs citations

55
times ranked

6620
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. <i>Psychological Medicine</i> , 2022, 52, 2441-2449.	4.5	6
2	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 289-302.	2.2	3
3	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	2.5	7
4	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	3.1	4
5	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE) CTN-0037 study. <i>Mental Health and Physical Activity</i> , 2021, 21, 100421.	1.8	0
6	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. <i>Journal of Affective Disorders</i> , 2021, 295, 1066-1071.	4.1	3
7	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. <i>Translational Psychiatry</i> , 2021, 11, 531.	4.8	6
8	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. <i>American Journal of Psychiatry</i> , 2020, 177, 143-154.	7.2	76
9	Discovery and replication of cerebral blood flow differences in major depressive disorder. <i>Molecular Psychiatry</i> , 2020, 25, 1500-1510.	7.9	28
10	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. <i>American Journal of Kidney Diseases</i> , 2020, 75, 457-460.	1.9	6
11	A Systematic Review and Meta-Analysis of Depression and Protein Energy Wasting in Kidney Disease. <i>Kidney International Reports</i> , 2020, 5, 318-330.	0.8	20
12	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). <i>Journal of Psychiatric Research</i> , 2020, 122, 22-32.	3.1	21
13	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. <i>Kidney360</i> , 2020, 1, 436-446.	2.1	4
14	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2020, 126, 19-25.	3.1	14
15	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. <i>Biological Psychiatry</i> , 2020, 88, 657-667.	1.3	23
16	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. <i>Depression and Anxiety</i> , 2020, 37, 771-783.	4.1	22
17	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. <i>Journal of Psychopharmacology</i> , 2019, 33, 185-193.	4.0	14
18	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EclinicalMedicine</i> , 2019, 10, 32-41.	7.1	19

#	ARTICLE	IF	CITATIONS
19	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. <i>American Journal of Nephrology</i> , 2019, 50, 37-47.	3.1	31
20	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2019, 113, 165-171.	3.1	33
21	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2019, 85, 872-880.	1.3	48
22	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. <i>Journal of Affective Disorders</i> , 2019, 245, 1070-1078.	4.1	17
23	The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. <i>Depression and Anxiety</i> , 2019, 36, 313-320.	4.1	7
24	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. <i>Journal of Psychiatric Research</i> , 2018, 102, 65-71.	3.1	14
25	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. <i>JAMA Psychiatry</i> , 2018, 75, 547.	11.0	125
26	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 1-8.	1.1	9
27	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. <i>Magnetic Resonance Imaging</i> , 2018, 45, 26-33.	1.8	28
28	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. <i>Molecular Neuropsychiatry</i> , 2018, 4, 7-19.	2.9	12
29	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. <i>Personalized Medicine in Psychiatry</i> , 2018, 9-10, 1-7.	0.1	5
30	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. <i>BMC Cancer</i> , 2018, 18, 744.	2.6	7
31	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). <i>Journal of Clinical Psychiatry</i> , 2018, 79, 41-47.	2.2	5
32	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 T 6, 22-30.	1.1	22
33	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1876.	7.4	99
34	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1075-1082.	2.2	53
35	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1036-1042.	2.2	15
36	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. <i>Journal of Psychiatric Research</i> , 2016, 78, 11-23.	3.1	216

#	ARTICLE	IF	CITATIONS
37	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2016, 200, 156-158.	4.1	15
38	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. <i>General Hospital Psychiatry</i> , 2016, 42, 60-66.	2.4	9
39	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 1196-1204.	7.2	40
40	Brain imaging demonstrates a reduced neural impact of eating in obesity. <i>Obesity</i> , 2016, 24, 829-836.	3.0	17
41	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. <i>American Journal on Addictions</i> , 2016, 25, 215-220.	1.4	4
42	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2016, 33, 56-65.	4.1	43
43	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 88-97.	2.1	23
44	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. <i>PLoS ONE</i> , 2016, 11, e0167901.	2.5	26
45	Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. <i>Human Brain Mapping</i> , 2015, 36, 3472-3485.	3.6	136
46	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. <i>American Journal of Psychiatry</i> , 2015, 172, 1014-1021.	7.2	30
47	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. <i>American Journal of Psychiatry</i> , 2015, 172, 881-891.	7.2	87
48	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 677-684.	2.2	177
49	The Montgomery Åsberg and the Hamilton ratings of depression: A comparison of measures. <i>European Neuropsychopharmacology</i> , 2006, 16, 601-611.	0.7	183
50	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. <i>Journal of Affective Disorders</i> , 2006, 95, 115-118.	4.1	33
51	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. <i>Biological Psychiatry</i> , 2003, 54, 573-583.	1.3	2,981
52	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. <i>Neuropsychopharmacology</i> , 2001, 25, 131-138.	5.4	45
53	The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. <i>International Journal of Methods in Psychiatric Research</i> , 2000, 9, 45-59.	2.1	328
54	Long-term results of interstitial implant in locally advanced cervical cancer:A retrospective study of 50 cases. <i>Radiation Oncology Investigations</i> , 1996, 4, 33-40.	0.9	2